Drug Target Review

MAY 27, 2024

Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival. How does the company see antibody-drug conjugates (ADCs) fitting into this approach?

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

The Pharma Data

NOVEMBER 22, 2021

Within close propinquity to AstraZeneca’s new centre is the University of Cambridge’s School of Clinical Medicine, the Medical Research Council Laboratory of Molecular Biology, Cancer Research UK and the Royal Papworth and Addenbrooke’s Hospitals, among others. region in the US, and Gothenburg in Sweden.

Molecular Biology 52

Molecular Biology Laboratories Engineering Hospitals 52

Broad Institute

JANUARY 30, 2024

He majored in biological chemistry at the University of Chicago and during his junior year, he had a fortuitous meeting with his academic advisor about finding a student research position that would let him dive more deeply into the molecular details of biological systems. A combined MD/PhD program offered both opportunities.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Codon

MARCH 12, 2023

I recently asked for recommendations of “classic” papers in molecular biology. Another phase 3 trial for hemophilia A found that annual bleeding rates “decreased by 84.5% FDA to start a Phase II trial for its gene therapy, called NTLA-2002 , to treat an inflammatory disease called hereditary angioedema.

DNA 52

DNA Engineering Therapies RNA 52

Codon

JUNE 26, 2023

The company behind the latter work, SNIPR BIOME , also recently announced results from a phase I clinical trial. A fifth clinical trial for base editing is now enrolling patients. It’s a phase I/II clinical trial for people with relapsed or refractory T-cell acute lymphoblastic leukemia. coli in mice. It will cost $3.2

DNA 52

DNA Therapies Engineering Clinical Trials 52

Codon

JUNE 26, 2023

The company behind the latter work, SNIPR BIOME , also recently announced results from a phase I clinical trial. A fifth clinical trial for base editing is now enrolling patients. It’s a phase I/II clinical trial for people with relapsed or refractory T-cell acute lymphoblastic leukemia. coli in mice. It will cost $3.2

DNA 52

DNA Therapies Engineering Clinical Trials 52